Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Mabion S.A. is a biotechnology company based in Poland, primarily focused on developing monoclonal antibodies for the treatment of various diseases, including cancer and autoimmune disorders. The company is positioned in a niche market with a competitive advantage stemming from its proprietary technology platform for biologics production, although it currently faces significant financial challenges.
Mabion generates revenue through collaborations and partnerships with larger pharmaceutical companies for the development and commercialization of its biopharmaceutical products. The company leverages its proprietary technology to produce complex biologics, which provides a competitive edge in terms of cost and efficiency.
Progress in clinical trials for lead product candidates, particularly MabionCD20
Partnership announcements with larger pharmaceutical firms
Regulatory approvals for new therapies
Market sentiment towards biotechnology sector trends
Regulatory changes affecting drug approval processes
Technological disruption in biopharmaceutical manufacturing
Emergence of biosimilars that could undercut pricing for Mabion's products
Increased competition from larger biotech firms with more resources
High cash burn rate leading to liquidity concerns
Debt levels that could become burdensome if revenue does not materialize
moderate - The biotechnology sector can be sensitive to economic conditions as funding for R&D may fluctuate with economic cycles.
Higher interest rates can increase the cost of capital for biotech firms like Mabion, potentially affecting their ability to finance R&D projects and impacting valuations.
minimal - The company has a manageable debt level, and its operations are not heavily dependent on credit markets.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector may be interested.
high - The stock has demonstrated significant volatility, reflective of the biotech sector's inherent risks.
